Differentiated plasma cell myeloma presenting as a solitary spinal amyloidoma: A case report, possible pitfall and review to the literature. Brawanski N et al. Clin Neurol Neurosurg. 2015 Jun 10;137:1-4. doi: 10.1016/j.clineuro.2015.05.027. [Epub ahead of print]. Regulatory Perspective on Minimal Residual Disease Flow Cytometry Testing in Multiple Myeloma. Gormley NJ et al. Cytometry B Clin Cytom. 2015 Jun 23. doi: 10.1002/cyto.b.21268. [Epub ahead of…
Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy. Teh BW et al. Br J Haematol. 2015 Jun 24. doi: 10.1111/bjh.13532. [Epub ahead of print]. Induction therapy alters plasma fibrin clot properties in multiple myeloma patients: association with thromboembolic complications. Undas A et al. Blood Coagul Fibrinolysis. 2015 Jun 11. [Epub…
The Feasibility and Efficacy of Dose-Adjusted Bortezomib, Melphalan and Dexamethasone for Transplantation-Ineligible Patients with Newly Diagnosed Multiple Myeloma. Obama K. Acta Haematol. 2015 Jun 11;134(4):229-230. [Epub ahead of print]/ Biosimilar filgrastim (Zarzio®) vs Lenograstim (Myelostim®) for peripheral blood stem cell mobilization in adult patients with myeloma and lymphoma: A single center experience. Marchesi F et al. Leuk Lymphoma. 2015 Jun 23:1-12.…
Comparison of Percutaneous Vertebroplasty and Balloon Kyphoplasty for the Treatment of Single Level Vertebral Compression Fractures: A Meta-analysis of the Literature. Wang H et al. Pain Physician. 2015 May-Jun;18(3):209-22. The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Diel IJ et al. Eur J Cancer. 2015 May 11. pii: S0959-8049(15)00373-1. doi: 10.1016/j.ejca.2015.04.017.…
Multiple myeloma: new uses for available agents, excitement for the future. Anderson KC. J Natl Compr Canc Netw. 2015 May;13(5 Suppl):694-6. Expanding role of lenalidomide in hematologic malignancies. Ghosh N et al. Cancer Manag Res. 2015 May 2;7:105-19. doi: 10.2147/CMAR.S81310. eCollection 2015. A Rare Variant of Multiple Myeloma; Non-Secretory Myeloma with diffuse osteolytic lesions. Sultan S et al. Gulf J Oncolog. 2015 May;1(18):28-31. Mapping Functions in…
Serous macular detachment, yellow macular deposits, and prominent middle limiting membrane in multiple myeloma. Dogan B et al. Ther Clin Risk Manag. 2015 Apr 30;11:683-9. doi: 10.2147/TCRM.S79232. eCollection 2015. Contribution of Clostridium difficile infection to the development of lower gastrointestinal adverse events during autologous stem cell transplantation. Apewokin S et al, Transpl Infect Dis. 2015 May 19. doi: 10.1111/tid.12403. [Epub ahead of…
Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma. Poenisch W et al. J Cancer Res Clin Oncol. 2015 May 15. [Epub ahead of print]. High-dose therapy and autologous stem cell transplant in older adults with multiple myeloma. Wildes TM et al. Bone Marrow Transplant. 2015 May 11. doi: 10.1038/bmt.2015.106. [Epub…
Autologous Stem-Cell Transplantation Without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah’s Witnesses. Ford PA et al. J Clin Oncol. 2015 Apr 13. pii: JCO.2014.57.9912. [Epub ahead of print]. Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosedmultiple myeloma patients with severe renal impairment. Zannetti BA et al. Am J Hematol. 2015 Apr 8. doi: 10.1002/ajh.24035.…
Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition. Stetler-Stevenson M et al. Cytometry B Clin Cytom. 2015 Apr 23. doi: 10.1002/cyto.b.21249. [Epub ahead of print]. Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma. Cejalvo MJ et al. Future Oncol. 2015 Apr 10:1-16. [Epub ahead of print]. Lenalidomide in multiple myeloma. Kim Y et al. Expert Rev Anticancer Ther. 2015 May;15(5):491-7. doi: 10.1586/14737140.2015.1033407.…
Thromboelastography, thrombin generation test and thrombodynamics reveal hypercoagulability in patients with multiple myeloma. Gracheva MA et al. Leuk Lymphoma. 2015 Apr 24:1-35. [Epub ahead of print]. Neurotoxicity of stem cell mobilization chemotherapy with vinorelbine in myeloma patients after bortezomib treatment. Keller S et al. Leuk Res. 2015 Mar 28. pii: S0145-2126(15)00086-7. doi: 10.1016/j.leukres.2015.03.015. [Epub ahead of print]. Subcutaneous bortezomib in multiple myeloma patients induces similar…